You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBumetanide
Accession NumberDB00887  (APRD00294)
TypeSmall Molecule
GroupsApproved
Description

A sulfamyl diuretic. [PubChem]

Structure
Thumb
Synonyms
3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid
3-Butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
3-Butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
3-Butylamino-4-phenoxy-5-sulfamoylbenzoic acid
Bumetanida
Bumetanidum
External Identifiers
  • a684051
  • CS 380
  • Ro 10-6338
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bumetanidetablet.5 mg/1oralEdenbridge Pharmaceuticals, LLC2015-10-15Not applicableUs
Bumetanidetablet2 mg/1oralEdenbridge Pharmaceuticals, LLC2015-10-15Not applicableUs
Bumetanidetablet1 mg/1oralEdenbridge Pharmaceuticals, LLC2015-10-15Not applicableUs
Burinex - Tab 2mgtablet2 mgoralLeo Pharma Inc1996-12-312004-07-23Canada
Burinex Tab 1mgtablet1 mgoralLeo Pharma Inc1993-12-31Not applicableCanada
Burinex Tab 5mgtablet5 mgoralLeo Pharma Inc1993-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bumetanidetablet1 mg/1oralAvera Mc Kennan Hospital2015-03-26Not applicableUs
Bumetanidetablet.5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-10-16Not applicableUs
Bumetanidetablet2 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-16Not applicableUs
Bumetanidetablet.5 mg/1oralTeva Pharmaceuticals USA Inc2007-10-16Not applicableUs
Bumetanidetablet1 mg/1oralbryant ranch prepack2007-10-16Not applicableUs
Bumetanideinjection.25 mg/mLintramuscular; intravenousCardinal Health1995-03-01Not applicableUs
Bumetanidetablet.5 mg/1oralAv Kare, Inc.2015-01-26Not applicableUs
Bumetanidetablet1 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-10-16Not applicableUs
Bumetanidetablet1 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-16Not applicableUs
Bumetanidetablet2 mg/1oralSt Marys Medical Park Pharmacy2014-08-20Not applicableUs
Bumetanidetablet2 mg/1oralPhysicians Total Care, Inc.2006-12-13Not applicableUs
Bumetanidetablet1 mg/1oralSt Marys Medical Park Pharmacy2014-05-22Not applicableUs
Bumetanidetablet.5 mg/1oralPhysicians Total Care, Inc.2000-11-29Not applicableUs
Bumetanidetablet2 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-10-16Not applicableUs
Bumetanideinjection, solution.25 mg/mLintramuscular; intravenousHospira, Inc.1994-10-31Not applicableUs
Bumetanidetablet2 mg/1oralAvera Mc Kennan Hospital2015-09-11Not applicableUs
Bumetanidetablet1 mg/1oralAidarex Pharmaceuticals LLC2007-10-16Not applicableUs
Bumetanidetablet2 mg/1oralEon Labs, Inc.1996-11-21Not applicableUs
Bumetanidetablet1 mg/1oralCardinal Health2011-04-29Not applicableUs
Bumetanidetablet1 mg/1oralPhysicians Total Care, Inc.2009-02-16Not applicableUs
Bumetanidetablet1 mg/1oralCarilion Materials Management1996-11-21Not applicableUs
Bumetanideinjection.25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2008-04-30Not applicableUs
Bumetanidetablet1 mg/1oralEon Labs, Inc.1996-11-21Not applicableUs
Bumetanideinjection, solution.25 mg/mLintramuscular; intravenousCardinal Health2011-11-16Not applicableUs
Bumetanidetablet2 mg/1oralUnit Dose Services2007-10-16Not applicableUs
Bumetanidetablet.5 mg/1oralCarilion Materials Management2007-10-16Not applicableUs
Bumetanideinjection.25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2008-04-30Not applicableUs
Bumetanidetablet.5 mg/1oralEon Labs, Inc.1996-11-21Not applicableUs
Bumetanideinjection, solution.25 mg/mLintranodal; intravenousCardinal Health2011-11-16Not applicableUs
Bumetanidetablet1 mg/1oralUnit Dose Services2007-10-16Not applicableUs
Bumetanidetablet1 mg/1oralAvera Mc Kennan Hospital2015-09-28Not applicableUs
Bumetanideinjection.25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2008-04-30Not applicableUs
Bumetanidetablet2 mg/1oralTeva Pharmaceuticals USA Inc2007-10-16Not applicableUs
Bumetanideinjection, solution.25 mg/mLintramuscular; intravenousCardinal Health2011-11-16Not applicableUs
Bumetanidetablet2 mg/1oralAv Kare, Inc.2015-01-26Not applicableUs
Bumetanidetablet2 mg/1oralAvera Mc Kennan Hospital2015-03-13Not applicableUs
Bumetanideinjection.25 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2008-04-30Not applicableUs
Bumetanidetablet1 mg/1oralTeva Pharmaceuticals USA Inc2007-10-16Not applicableUs
Bumetanideinjection.25 mg/mLintramuscular; intravenousCardinal Health2009-01-27Not applicableUs
Bumetanidetablet1 mg/1oralAv Kare, Inc.2015-01-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BumexF. Hoffmann-La Roche Ltd.
BurinexF. Hoffmann-La Roche Ltd.
FordiuranLEO Pharma A/S
LunetoronDaiichi Sankyo
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0Y2S3XUQ5H
CAS number28395-03-1
WeightAverage: 364.416
Monoisotopic: 364.10929245
Chemical FormulaC17H20N2O5S
InChI KeyInChIKey=MAEIEVLCKWDQJH-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
IUPAC Name
3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
SMILES
CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylethers
Direct ParentDiphenylethers
Alternative Parents
Substituents
  • Diphenylether
  • Diaryl ether
  • Aminobenzenesulfonamide
  • Benzenesulfonamide
  • Aminobenzoic acid or derivatives
  • Aminobenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Phenylalkylamine
  • Substituted aniline
  • Benzoyl
  • Secondary aliphatic/aromatic amine
  • Aniline
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.
PharmacodynamicsBumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. There is however no reason not to use bumetanide as a first choice drug. The main difference between the two substances is in bioavailability. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect. Bumetanide is 40 times more potent than furosemide (for patients with normal renal function).
Mechanism of actionBumetanide interferes with renal cAMP and/or inhibits the sodium-potassium ATPase pump. Bumetanide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis.
Related Articles
AbsorptionBumetanide is completely absorbed (80%), and the absorption is not altered when taken with food. Bioavailability is almost complete.
Volume of distributionNot Available
Protein binding97%
Metabolism

45% is secreted unchanged. Urinary and biliary metabolites are formed by oxidation of the N-butyl side chain.

Route of eliminationOral administration of carbon-14 labeled Bumex to human volunteers revealed that 81% of the administered radioactivity was excreted in the urine, 45% of it as unchanged drug. Biliary excretion of Bumex amounted to only 2% of the administered dose.
Half life60-90 minutes
Clearance
  • 0.2 – 1.1 mL/min/kg [preterm and full-term neonates with respiratory disorders]
  • 2.17 mL/min/kg [neonates receiving bumetanide for volume overload]
  • 1.8 +/- 0.3 mL/min/kg [geriatric subjects]
  • 2.9 +/- 0.2 mL/min/kg [younger subjects]
ToxicityOverdosage can lead to acute profound water loss, volume and electrolyte depletion, dehydration, reduction of blood volume and circulatory collapse with a possibility of vascular thrombosis and embolism. Electrolyte depletion may be manifested by weakness, dizziness, mental confusion, anorexia, lethargy, vomiting and cramps. Treatment consists of replacement of fluid and electrolyte losses by careful monitoring of the urine and electrolyte output and serum electrolyte levels.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bumetanide Action PathwayDrug actionSMP00088
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier-0.6636
Caco-2 permeable-0.6492
P-glycoprotein substrateNon-substrate0.509
P-glycoprotein inhibitor INon-inhibitor0.8765
P-glycoprotein inhibitor IINon-inhibitor0.8103
Renal organic cation transporterNon-inhibitor0.8966
CYP450 2C9 substrateNon-substrate0.6368
CYP450 2D6 substrateNon-substrate0.7656
CYP450 3A4 substrateNon-substrate0.6059
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7344
Ames testNon AMES toxic0.6794
CarcinogenicityNon-carcinogens0.7294
BiodegradationNot ready biodegradable0.9837
Rat acute toxicity1.8148 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9319
hERG inhibition (predictor II)Non-inhibitor0.8591
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
  • Validus pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Sandoz inc
Packagers
Dosage forms
FormRouteStrength
Injectionintramuscular; intravenous.25 mg/mL
Injection, solutionintramuscular; intravenous.25 mg/mL
Injection, solutionintranodal; intravenous.25 mg/mL
Tabletoral.5 mg/1
Tabletoral1 mg/1
Tabletoral2 mg/1
Tabletoral2 mg
Tabletoral1 mg
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Bumex 2 mg tablet1.65USD tablet
Bumetanide 2 mg tablet1.04USD tablet
Bumex 1 mg tablet0.98USD tablet
Bumex 0.5 mg tablet0.7USD tablet
Bumetanide 1 mg tablet0.51USD tablet
Bumetanide 0.5 mg tablet0.38USD tablet
Bumetanide 0.25 mg/ml vial0.25USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point230-231Felt, P.W.; US. Patent 3,634,583; January 11, 1972; assigned to Lovens Kemiske Fabrik Produktionsaktieselskab, Denmark.
water solubility>20 mg/mL (in base)Not Available
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0257 mg/mLALOGPS
logP3.44ALOGPS
logP2.42ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)4.69ChemAxon
pKa (Strongest Basic)2.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.72 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity95.78 m3·mol-1ChemAxon
Polarizability37.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Felt, P.W.; US. Patent 3,634,583; January 11, 1972; assigned to Lovens Kemiske Fabrik
Produktionsaktieselskab, Denmark.

General ReferencesNot Available
External Links
ATC CodesC03CA02C03CB02C03EB02
AHFS Codes
  • 40:28.08
PDB EntriesNot Available
FDA labelDownload (206 KB)
MSDSDownload (72.8 KB)
Interactions
Drug Interactions
Drug
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Bumetanide.
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Bumetanide.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bumetanide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Bumetanide.
AlfuzosinAlfuzosin may increase the hypotensive activities of Bumetanide.
AllopurinolThe risk or severity of adverse effects can be increased when Bumetanide is combined with Allopurinol.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Bumetanide.
AmifostineBumetanide may increase the hypotensive activities of Amifostine.
AmikacinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amikacin.
ArbekacinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Arbekacin.
BrimonidineBrimonidine may increase the antihypertensive activities of Bumetanide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Bumetanide.
ButabarbitalButabarbital may increase the hypotensive activities of Bumetanide.
ButethalButethal may increase the hypotensive activities of Bumetanide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bumetanide.
CaffeineThe risk or severity of adverse effects can be increased when Caffeine is combined with Bumetanide.
CanagliflozinCanagliflozin may increase the hypotensive activities of Bumetanide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Bumetanide.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Bumetanide.
CisplatinBumetanide may increase the nephrotoxic activities of Cisplatin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Bumetanide.
ColesevelamColesevelam can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bumetanide.
DiazoxideDiazoxide may increase the hypotensive activities of Bumetanide.
DigoxinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bumetanide.
DofetilideBumetanide may increase the QTc-prolonging activities of Dofetilide.
DuloxetineBumetanide may increase the orthostatic hypotensive activities of Duloxetine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bumetanide.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Bumetanide.
FlunisolideFlunisolide may increase the hypokalemic activities of Bumetanide.
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Bumetanide.
FosphenytoinFosphenytoin may decrease the diuretic activities of Bumetanide.
FramycetinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Framycetin.
GentamicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Gentamicin.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Bumetanide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Bumetanide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Bumetanide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Bumetanide.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Bumetanide.
HexobarbitalHexobarbital may increase the hypotensive activities of Bumetanide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bumetanide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bumetanide.
InfliximabInfliximab may decrease the diuretic activities of Bumetanide.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Bumetanide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Bumetanide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Bumetanide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Bumetanide.
Insulin HumanThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Bumetanide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Bumetanide.
IvabradineBumetanide may increase the arrhythmogenic activities of Ivabradine.
KanamycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Kanamycin.
LevodopaBumetanide may increase the orthostatic hypotensive activities of Levodopa.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bumetanide.
LicoriceLicorice may increase the hypokalemic activities of Bumetanide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Bumetanide.
LithiumThe serum concentration of Lithium can be decreased when it is combined with Bumetanide.
MecamylamineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Mecamylamine.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Bumetanide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Bumetanide.
MethohexitalMethohexital may increase the hypotensive activities of Bumetanide.
MethotrexateThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Methotrexate.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bumetanide.
MolsidomineMolsidomine may increase the hypotensive activities of Bumetanide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Bumetanide.
MoxonidineMoxonidine may increase the hypotensive activities of Bumetanide.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bumetanide.
NeomycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Neomycin.
NetilmicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Netilmicin.
NicorandilNicorandil may increase the hypotensive activities of Bumetanide.
ObinutuzumabBumetanide may increase the hypotensive activities of Obinutuzumab.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Bumetanide.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bumetanide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bumetanide.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bumetanide.
PentobarbitalPentobarbital may increase the hypotensive activities of Bumetanide.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bumetanide.
PerindoprilBumetanide may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bumetanide.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Bumetanide.
PhenytoinPhenytoin may decrease the diuretic activities of Bumetanide.
PrimidonePrimidone may increase the hypotensive activities of Bumetanide.
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Bumetanide.
QuinineQuinine may increase the hypotensive activities of Bumetanide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bumetanide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Bumetanide.
RibostamycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ribostamycin.
RisperidoneThe risk or severity of adverse effects can be increased when Bumetanide is combined with Risperidone.
RituximabBumetanide may increase the hypotensive activities of Rituximab.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Bumetanide.
SecobarbitalSecobarbital may increase the hypotensive activities of Bumetanide.
SpectinomycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Spectinomycin.
StreptomycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Streptomycin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bumetanide.
SulpirideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sulpiride.
TadalafilTadalafil may increase the antihypertensive activities of Bumetanide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Bumetanide.
TobramycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Tobramycin.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Bumetanide.
TopiramateBumetanide may increase the hypokalemic activities of Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bumetanide.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Bumetanide.
TreprostinilTreprostinil may increase the hypotensive activities of Bumetanide.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bumetanide.
VardenafilVardenafil may increase the antihypertensive activities of Bumetanide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Bumetanide.
YohimbineYohimbine may decrease the antihypertensive activities of Bumetanide.
Food Interactions
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Thakker RV: Chloride channels in renal disease. Adv Nephrol Necker Hosp. 1999;29:289-98. [PubMed:10561751 ]
  2. Karolyi L, Koch MC, Grzeschik KH, Seyberth HW: The molecular genetic approach to "Bartter's syndrome". J Mol Med (Berl). 1998 Apr;76(5):317-25. [PubMed:9587066 ]
  3. Thakker RV: The role of renal chloride channel mutations in kidney stone disease and nephrocalcinosis. Curr Opin Nephrol Hypertens. 1998 Jul;7(4):385-8. [PubMed:9690036 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Long P, Mercer A, Begum R, Stephens GJ, Sihra TS, Jovanovic JN: Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37. doi: 10.1074/jbc.M805322200. Epub 2009 Jan 13. [PubMed:19141616 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A2
Uniprot ID:
P55011
Molecular Weight:
131445.825 Da
References
  1. Panet R, Marcus M, Atlan H: Overexpression of the Na(+)/K(+)/Cl(-) cotransporter gene induces cell proliferation and phenotypic transformation in mouse fibroblasts. J Cell Physiol. 2000 Jan;182(1):109-18. [PubMed:10567922 ]
  2. Evans RL, Park K, Turner RJ, Watson GE, Nguyen HV, Dennett MR, Hand AR, Flagella M, Shull GE, Melvin JE: Severe impairment of salivation in Na+/K+/2Cl- cotransporter (NKCC1)-deficient mice. J Biol Chem. 2000 Sep 1;275(35):26720-6. [PubMed:10831596 ]
  3. Wall SM, Fischer MP, Mehta P, Hassell KA, Park SJ: Contribution of the Na+-K+-2Cl- cotransporter NKCC1 to Cl- secretion in rat OMCD. Am J Physiol Renal Physiol. 2001 May;280(5):F913-21. [PubMed:11292635 ]
  4. Akar F, Jiang G, Paul RJ, O'Neill WC: Contractile regulation of the Na(+)-K(+)-2Cl(-) cotransporter in vascular smooth muscle. Am J Physiol Cell Physiol. 2001 Aug;281(2):C579-84. [PubMed:11443057 ]
  5. Jiang G, Klein JD, O'Neill WC: Growth factors stimulate the Na-K-2Cl cotransporter NKCC1 through a novel Cl(-)-dependent mechanism. Am J Physiol Cell Physiol. 2001 Dec;281(6):C1948-53. [PubMed:11698253 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein kinase binding
Specific Function:
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral Cl(-) exit in NaCl absorbing epithelia (By similarity). Isoform 4 has no transport activity.
Gene Name:
SLC12A4
Uniprot ID:
Q9UP95
Molecular Weight:
120648.73 Da
References
  1. Jean-Xavier C, Pflieger JF, Liabeuf S, Vinay L: Inhibitory postsynaptic potentials in lumbar motoneurons remain depolarizing after neonatal spinal cord transection in the rat. J Neurophysiol. 2006 Nov;96(5):2274-81. Epub 2006 Jun 28. [PubMed:16807348 ]
  2. Reid KH, Guo SZ, Iyer VG: Agents which block potassium-chloride cotransport prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. Brain Res. 2000 May 2;864(1):134-7. [PubMed:10793196 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein kinase binding
Specific Function:
Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in neurons.
Gene Name:
SLC12A5
Uniprot ID:
Q9H2X9
Molecular Weight:
126182.49 Da
References
  1. Reid KH, Guo SZ, Iyer VG: Agents which block potassium-chloride cotransport prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. Brain Res. 2000 May 2;864(1):134-7. [PubMed:10793196 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Pdz domain binding
Specific Function:
Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter. Can inhibit the chloride channel activity of ANO1. Plays a role in the chloride and bicarbonate homeostasis during sperm epididymal maturation and capacitation.
Gene Name:
CFTR
Uniprot ID:
P13569
Molecular Weight:
168139.895 Da
References
  1. Reddy MM, Quinton PM: Bumetanide blocks CFTR GCl in the native sweat duct. Am J Physiol. 1999 Jan;276(1 Pt 1):C231-7. [PubMed:9886939 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Cheng HF, Wang JL, Zhang MZ, McKanna JA, Harris RC: Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. J Clin Invest. 2000 Sep;106(5):681-8. [PubMed:10974021 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Molecular Weight:
38118.64 Da
References
  1. Hagenbuch B, Stieger B, Foguet M, Lubbert H, Meier PJ: Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10629-33. [PubMed:1961729 ]
  2. Platte HD, Honscha W, Schuh K, Petzinger E: Functional characterization of the hepatic sodium-dependent taurocholate transporter stably transfected into an immortalized liver-derived cell line and V79 fibroblasts. Eur J Cell Biol. 1996 May;70(1):54-60. [PubMed:8738419 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739 ]
  2. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Horz JA, Honscha W, Petzinger E: Bumetanide is not transported by the Ntcp or by the oatp: evidence for a third organic anion transporter in rat liver cells. Biochim Biophys Acta. 1996 Apr 19;1300(2):114-8. [PubMed:8652636 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 02, 2014 09:42